Suppr超能文献

老年综合评估测量的功能状态预测老年异基因造血细胞移植受者生存不良。

Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.

机构信息

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

出版信息

Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196. doi: 10.1016/j.bbmt.2019.08.022. Epub 2019 Sep 5.

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) has been increasingly offered to older adults with hematologic malignancies. However, optimal methods to determine fitness for alloHCT have yet to be defined. We evaluated the ability of a comprehensive geriatric assessment (CGA) to predict post-alloHCT outcomes in a single-center prospective cohort study of patients age 50 years and older. Outcomes included overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM). A total of 148 patients were included, with a median age of 62 years (range, 50 to 76 years). In multivariate regression analysis, several CGA measures of functional status were predictive of post-alloHCT outcomes, after adjusting for traditional prognostic factors. Any deficit in instrumental activities of daily living (IADL) was associated with inferior OS (hazard ratio [HR], 1.81, 95% confidence interval [CI], 1.07 to 3.08; P = .03) and PFS (HR, 1.85; 95% CI, 1.15 to 2.99; P = .01). A Medical Outcomes Study Physical Health scale (MOS-PH) score <85 was associated with inferior OS (HR, 1.96; 95% CI, 1.13 to 3.40; P = .02), PFS (HR, 1.75; 95% CI, 1.07 to 2.88; P = .03), and increased NRM (subdistribution HR, 2.57; 95% CI, 1.12 to 5.92; P = .03). MOS-PH score was also associated with the number of non-hematologic grade ≥3 adverse events within the first 100 days after alloHCT (rate ratio, 1.61; 95% CI, 1.04 to 2.49; P = .03). These findings support previous work suggesting that IADL is an important prognostic tool prior to alloHCT. MOS-PH is newly identified as an additional metric to identify older patients at higher risk of poor post-alloHCT outcomes, including toxicity and NRM.

摘要

异基因造血细胞移植(alloHCT)已越来越多地用于老年血液系统恶性肿瘤患者。然而,确定 alloHCT 适宜性的最佳方法尚未确定。我们评估了综合老年评估(CGA)在单中心前瞻性队列研究中预测 50 岁及以上患者 alloHCT 后结局的能力。结局包括总生存(OS)、无进展生存(PFS)和非复发死亡率(NRM)。共纳入 148 例患者,中位年龄 62 岁(范围 50 至 76 岁)。在多变量回归分析中,调整传统预后因素后,几项 CGA 功能性状态测量指标与 alloHCT 后结局相关。任何日常生活活动(IADL)的缺陷与较差的 OS(风险比[HR],1.81,95%置信区间[CI],1.07 至 3.08;P =.03)和 PFS(HR,1.85;95% CI,1.15 至 2.99;P =.01)相关。医学结局研究身体健康量表(MOS-PH)评分<85 与较差的 OS(HR,1.96;95% CI,1.13 至 3.40;P =.02)、PFS(HR,1.75;95% CI,1.07 至 2.88;P =.03)和增加的 NRM(亚分布 HR,2.57;95% CI,1.12 至 5.92;P =.03)相关。MOS-PH 评分也与 alloHCT 后 100 天内非血液学≥3 级不良事件的数量相关(率比,1.61;95% CI,1.04 至 2.49;P =.03)。这些发现支持先前的工作,表明 IADL 是 alloHCT 前重要的预后工具。MOS-PH 是新确定的另一个指标,用于识别 alloHCT 后结局较差(包括毒性和 NRM)风险较高的老年患者。

相似文献

1
Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.
Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196. doi: 10.1016/j.bbmt.2019.08.022. Epub 2019 Sep 5.
2
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.
Blood Adv. 2020 Jun 23;4(12):2810-2820. doi: 10.1182/bloodadvances.2020001719.
3
Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.
Transplant Cell Ther. 2022 Jun;28(6):309.e1-309.e9. doi: 10.1016/j.jtct.2022.02.022. Epub 2022 Mar 3.
4
Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults.
Transplant Cell Ther. 2021 Apr;27(4):344.e1-344.e5. doi: 10.1016/j.jtct.2021.01.001. Epub 2021 Jan 7.
6
The Prevalence of Pretransplant Frailty and Mental Distress in Hematopoietic Cell Transplantation and Association with Clinical Outcomes.
Transplant Cell Ther. 2024 Sep;30(9):919.e1-919.e9. doi: 10.1016/j.jtct.2024.05.026. Epub 2024 Jun 3.
8
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Transplant Cell Ther. 2021 May;27(5):410-422. doi: 10.1016/j.jtct.2021.02.030. Epub 2021 Feb 26.
9
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
Haematologica. 2014 Aug;99(8):1373-9. doi: 10.3324/haematol.2014.103655. Epub 2014 May 9.

引用本文的文献

1
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies.
Yonago Acta Med. 2025 Jul 17;68(3):169-179. doi: 10.33160/yam.2025.08.001. eCollection 2025 Aug.
3
Allogeneic Transplantation for Older Adults.
Adv Exp Med Biol. 2025;1475:9-40. doi: 10.1007/978-3-031-84988-6_2.
4
Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies.
Curr Treat Options Oncol. 2025 May;26(5):348-359. doi: 10.1007/s11864-025-01316-6. Epub 2025 Apr 10.
5
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.
Blood. 2025 Jun 12;145(24):2847-2856. doi: 10.1182/blood.2024024247.
7
Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies.
Blood Adv. 2024 Jul 23;8(14):3849-3858. doi: 10.1182/bloodadvances.2023011761.
8
Transplantation and Cellular Therapy for Older Adults-The MSK Approach.
Curr Hematol Malig Rep. 2024 Apr;19(2):82-91. doi: 10.1007/s11899-024-00725-y. Epub 2024 Feb 9.
9
Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.
Pharmaceutics. 2023 Dec 29;16(1):55. doi: 10.3390/pharmaceutics16010055.
10
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Transplant Cell Ther. 2024 Apr;30(4):415.e1-415.e16. doi: 10.1016/j.jtct.2024.01.062. Epub 2024 Jan 17.

本文引用的文献

1
Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.
Blood. 2019 Jul 25;134(4):374-382. doi: 10.1182/blood.2019000758. Epub 2019 Jun 5.
2
Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience.
Bone Marrow Transplant. 2018 Sep;53(9):1184-1187. doi: 10.1038/s41409-018-0151-3. Epub 2018 Mar 9.
4
Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful.
Cancer. 2017 Dec 1;123(23):4687-4700. doi: 10.1002/cncr.30936. Epub 2017 Aug 17.
5
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.
Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. Epub 2017 Jul 3.
9
Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates.
J Geriatr Oncol. 2014 Oct 1;5(4):422-30. doi: 10.1016/j.jgo.2014.04.004. Epub 2014 May 14.
10
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
Haematologica. 2014 Aug;99(8):1373-9. doi: 10.3324/haematol.2014.103655. Epub 2014 May 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验